Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(25%)
Results Posted
0%(0 trials)

Phase Distribution

No phase data available

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(3)

Detailed Status

Completed3
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%

Trials by Status

active_not_recruiting125%
completed375%

Recent Activity

1 active trials
Showing 4 of 4
active_not_recruiting

TACkLE Study - Tackling Adverse Chemotherapy-associated Late Effects

NCT02276430
completed

The GALLOP-11 Study

NCT05178030
completed

The Indol Profile; Exploring the Metabolic Profile of Neuroendocrine Tumors

NCT02815969
completed

Antibodies Causing Epilepsy Syndromes: The ACES Study.

NCT02802475

Clinical Trials (4)

Showing 4 of 4 trials
NCT02276430

TACkLE Study - Tackling Adverse Chemotherapy-associated Late Effects

Active Not Recruiting
NCT05178030

The GALLOP-11 Study

Completed
NCT02815969

The Indol Profile; Exploring the Metabolic Profile of Neuroendocrine Tumors

Completed
NCT02802475

Antibodies Causing Epilepsy Syndromes: The ACES Study.

Completed

All 4 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
4